Kisqali® Improves Outcomes for Premenopausal Women with HR+/HER2- Advanced Breast Cancer

Premenopausal breast cancer is a biologically distinct and more aggressive disease than postmenopausal breast cancer and is the leading cause of cancer death in women 20-59 years old12 3 Historically there younger women were treated the same as their olde [...]

Nerlynx Modestly Improves Survival of HER 2-Positive Early Stage Breast Cancer

Positive results from the clinical trial evaluating neratinib for the extended adjuvant treatment of early stage HER2-positive breast cancer following trastuzumab-based therapy ExteNET trial were presented at the European Society of Medical Oncology ESMO [...]

Verzenio Demonstrates Superior Progression-Free Survival in Advanced Breast Cancer

Recently released clinical trial results from the Phase 3 MONARCH 2 study showed that Verzenio abemaciclib a cyclin-dependent kinase CDK 4 38 6 inhibitor when administered in combination with fulvestrant significantly improves the time to cancer progressi [...]

Radius Health Receives FDA Fast Track Designation for Elacestrant

The US Food and Drug Administration FDA has granted Fast Track designation for elacestrant an investigational oral selective estrogen receptor down-regulatordegrader SERD as a treatment of women with ER and HER2- advanced or metastatic breast cancer Fast [...]